Main content 1 Menu 2 Search 3 Footer 4
+A
A
-A
High contrast
HOME JOURNAL CRITERIA NETWORK HELP ABOUT

Current criteria:

Regional:

WPRlM journal selection criteria(2023)

Minimum standards for the suspension and removal of WPRIM approved journals

Countries journal selection criteria:

Philippines

Submit your journal information>

Contact NJSCs>

Chinese Journal of Cancer

2002 (v1, n1) to Present ISSN: 1671-8925

Articles

About

Year of publication

Save Email

Sort by

Best match
Relevance
PubYear
JournalTitle

DISPLAY OPTIONS

Format:

Per page:

Save citations to file

Selection:

Format:

Create file Cancel

Email citations

To:

Please check your email address first!

Selection:

Format:

Send email Cancel

1078

results

page

of 108

1

Cite

Cite

Copy

Share

Share

Copy

Novel anti-melanoma treatment: focus on immunotherapy.

Meng-Ze HAO ; Wen-Ya ZHOU ; Xiao-Ling DU ; Ke-Xin CHEN ; Guo-Wen WANG ; Yun YANG ; Ji-Long YANG

Chinese Journal of Cancer.2014;33(9):458-465. doi:10.5732/cjc.014.10118

Melanoma is an intractable cancer that is aggressive, lethal, and metastatic. The prognosis of advanced melanoma is very poor because it is insensitive to chemotherapy and radiotherapy. The incidence of melanoma has been ascending stably for years worldwide, accompanied by increasing mortality. New approaches to managing this deadly disease are much anticipated to enhance the cure rate and to extend clinical benefits to patients with metastatic melanoma. Due to its high degree of immunogenicity, melanoma could be a good target for immunotherapy, which has been developed for decades and has achieved certain progress. This article provides an overview of immunotherapy for melanoma.
Humans ; Immunotherapy ; Melanoma ; therapy

Humans ; Immunotherapy ; Melanoma ; therapy

2

Cite

Cite

Copy

Share

Share

Copy

Cancer immunotherapy in clinical practice -- the past, present, and future.

Gaurav GOEL ; Weijing SUN

Chinese Journal of Cancer.2014;33(9):445-457. doi:10.5732/cjc.014.10123

Considerable progress has been made in the field of cancer immunotherapy in recent years. This has been made possible in large part by the identification of new immune-based cellular targets and the development of novel approaches aimed at stimulating the immune system. The role played by the immunosuppressive microenvironment in the development of tumors has been established. The success of checkpoint-inhibiting antibodies and cancer vaccines has marked the beginning of a new era in cancer treatment. This review highlights the clinically relevant principles of cancer immunology and various immunotherapeutic approaches that have either already entered mainstream oncologic practice or are currently in the process of being evaluated in clinical trials. Furthermore, the current barriers to the development of effective immunotherapies and the potential strategies of overcoming them are also discussed.
Antibodies ; therapeutic use ; Antineoplastic Agents ; Cancer Vaccines ; therapeutic use ; Cell Cycle Checkpoints ; Humans ; Immunotherapy ; methods ; Neoplasms ; therapy

Antibodies ; therapeutic use ; Antineoplastic Agents ; Cancer Vaccines ; therapeutic use ; Cell Cycle Checkpoints ; Humans ; Immunotherapy ; methods ; Neoplasms ; therapy

3

Cite

Cite

Copy

Share

Share

Copy

Immune checkpoint inhibitors in clinical trials.

Elad SHARON ; Howard STREICHER ; Priscila GONCALVES ; Helen X CHEN

Chinese Journal of Cancer.2014;33(9):434-444. doi:10.5732/cjc.014.10122

Immunology-based therapy is rapidly developing into an effective treatment option for a surprising range of cancers. We have learned over the last decade that powerful immunologic effector cells may be blocked by inhibitory regulatory pathways controlled by specific molecules often called "immune checkpoints." These checkpoints serve to control or turn off the immune response when it is no longer needed to prevent tissue injury and autoimmunity. Cancer cells have learned or evolved to use these mechanisms to evade immune control and elimination. The development of a new therapeutic class of drugs that inhibit these inhibitory pathways has recently emerged as a potent strategy in oncology. Three sets of agents have emerged in clinical trials exploiting this strategy. These agents are antibody-based therapies targeting cytotoxic T-lymphocyte antigen 4 (CTLA4), programmed cell death 1 (PD-1), and programmed cell death ligand 1 (PD-L1). These inhibitors of immune inhibition have demonstrated extensive activity as single agents and in combinations. Clinical responses have been seen in melanoma, renal cell carcinoma, non-small cell lung cancer, and several other tumor types. Despite the autoimmune or inflammatory immune-mediated adverse effects which have been seen, the responses and overall survival benefits exhibited thus far warrant further clinical development.
B7-H1 Antigen ; CTLA-4 Antigen ; Carcinoma, Non-Small-Cell Lung ; Carcinoma, Renal Cell ; Cell Cycle Checkpoints ; immunology ; Immunotherapy ; adverse effects ; methods ; mortality ; Melanoma ; Neoplasms ; Programmed Cell Death 1 Receptor

B7-H1 Antigen ; CTLA-4 Antigen ; Carcinoma, Non-Small-Cell Lung ; Carcinoma, Renal Cell ; Cell Cycle Checkpoints ; immunology ; Immunotherapy ; adverse effects ; methods ; mortality ; Melanoma ; Neoplasms ; Programmed Cell Death 1 Receptor

4

Cite

Cite

Copy

Share

Share

Copy

The human application of gene therapy to re-program T-cell specificity using chimeric antigen receptors.

Alan D GUERRERO ; Judy S MOYES ; Laurence J N COOPER

Chinese Journal of Cancer.2014;33(9):421-433. doi:10.5732/cjc.014.10100

The adoptive transfer of T cells is a promising approach to treat cancers. Primary human T cells can be modified using viral and non-viral vectors to promote the specific targeting of cancer cells via the introduction of exogenous T-cell receptors (TCRs) or chimeric antigen receptors (CARs). This gene transfer displays the potential to increase the specificity and potency of the anticancer response while decreasing the systemic adverse effects that arise from conventional treatments that target both cancerous and healthy cells. This review highlights the generation of clinical-grade T cells expressing CARs for immunotherapy, the use of these cells to target B-cell malignancies and, particularly, the first clinical trials deploying the Sleeping Beauty gene transfer system, which engineers T cells to target CD19+ leukemia and non-Hodgkin's lymphoma.
B-Lymphocytes ; Gene Transfer Techniques ; Genetic Therapy ; Genetic Vectors ; Humans ; Immunotherapy, Adoptive ; Leukemia ; Lymphoma, B-Cell ; therapy ; Lymphoma, Non-Hodgkin ; therapy ; Neoplasms ; Receptors, Antigen ; Receptors, Antigen, T-Cell ; Receptors, CCR1 ; T-Cell Antigen Receptor Specificity ; T-Lymphocytes

B-Lymphocytes ; Gene Transfer Techniques ; Genetic Therapy ; Genetic Vectors ; Humans ; Immunotherapy, Adoptive ; Leukemia ; Lymphoma, B-Cell ; therapy ; Lymphoma, Non-Hodgkin ; therapy ; Neoplasms ; Receptors, Antigen ; Receptors, Antigen, T-Cell ; Receptors, CCR1 ; T-Cell Antigen Receptor Specificity ; T-Lymphocytes

5

Cite

Cite

Copy

Share

Share

Copy

James P. Allison received the 2014 Szent-Györgi Prize for Progress in Cancer Research.

Jie ZHAO ; Peter SCULLY ; Sujuan BA

Chinese Journal of Cancer.2014;33(9):416-420. doi:10.5732/cjc.014.10125

The Szent-Györgyi Prize for Progress in Cancer Research is a prestigious scientific award established by the National Foundation for Cancer Research (NFCR) -- a leading cancer research charitable organization in the United States that is committed to supporting innovative cancer research on the global scale that aims to cure cancer. Each year, the Szent-Györgyi Prize honors an outstanding researcher whose original discoveries have expanded our understanding of cancer and resulted in notable advances in cancer prevention, diagnosis, or treatment. The prize also promotes public awareness of the importance of basic cancer research and encourages the sustained investment needed to accelerate the translation of these research discoveries into new cancer treatments. This report highlights the history and mission of the Szent-Györgyi Prize, its role in promoting discovery-oriented cancer research, and the pioneering work led by the 2014 prize winner, Dr. James Allison. Dr. Allison's work in the area of cancer immunotherapy led to the successful development of immune checkpoint therapy, and the first drug approved by the United States Food and Drug Administration for the treatment of metastatic melanoma.
Awards and Prizes ; Humans ; Immunotherapy ; Melanoma ; Neoplasms ; United States

Awards and Prizes ; Humans ; Immunotherapy ; Melanoma ; Neoplasms ; United States

6

Cite

Cite

Copy

Share

Share

Copy

Predictive factors for the local recurrence and distant metastasis of phyllodes tumors of the breast: a retrospective analysis of 192 cases at a single center.

Jing WEI ; ; Yu-Ting TAN ; Yu-Cen CAI ; Zhong-Yu YUAN ; Dong YANG ; Shu-Sen WANG ; Rou-Jun PENG ; Xiao-Yu TENG ; Dong-Geng LIU ; Yan-Xia SHI

Chinese Journal of Cancer.2014;33(10):492-500. doi:10.5732/cjc.014.10048

The local recurrence rate of phyllodes tumors of the breast varies widely among different subtypes, and distant metastasis is associated with poor survival. This study aimed to identify factors that are predictive of local recurrence-free survival (LRFS), distant metastasis-free survival (DMFS), and overall survival (OS) in patients with phyllodes tumors of the breast. Clinical data of all patients with a phyllodes tumor of the breast (n = 192) treated at Sun Yat-sen University Cancer Center between March 1997 and December 2012 were reviewed. The Pearson Χ² test was used to investigate the relationship between clinical features of patients and histotypes of tumors. Univariate and multivariate Cox regression analyses were performed to identify factors that are predictive of LRFS, DMFS, and OS. In total, 31 (16.1%) patients developed local recurrence, and 12 (6.3%) developed distant metastasis. For the patients who developed local recurrence, the median age at the diagnosis of primary tumor was 33 years (range, 17-56 years), and the median size of primary tumor was 6.0 cm (range, 0.8-18 cm). For patients who developed distant metastasis, the median age at the diagnosis of primary tumor was 46 years (range, 24-68 years), and the median size of primary tumor was 5.0 cm (range, 0.8-18 cm). In univariate analysis, age, size, hemorrhage, and margin status were found to be predictive factors for LRFS (P = 0.009, 0.024, 0.004, and 0.001, respectively), whereas histotype, epithelial hyperplasia, margin status, and local recurrence were predictors of DMFS (P = 0.001, 0.007, 0.007, and < 0.001, respectively). In multivariate analysis, independent prognostic factors for LRFS included age [hazard ratio (HR) = 3.045, P = 0.005], tumor size (HR = 2.668, P = 0.013), histotype (HR = 1.715, P = 0.017), and margin status (HR = 4.530, P< 0.001). Histotype (DMFS: HR = 4.409, P = 0.002; OS: HR = 4.194, P = 0.003) and margin status (DMFS: HR = 2.581, P = 0.013; OS: HR = 2.507, P = 0.020) were independent predictors of both DMFS and OS. In this cohort, younger age, a larger tumor size, a higher tumor grade, and positive margins were associated with lower rates of LRFS. Histotype and margin status were found to be independent predictors of DMFS and OS.
Adolescent ; Adult ; Breast Neoplasms ; Female ; Humans ; Middle Aged ; Multivariate Analysis ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Phyllodes Tumor ; Prognosis ; Retrospective Studies ; Risk Factors

Adolescent ; Adult ; Breast Neoplasms ; Female ; Humans ; Middle Aged ; Multivariate Analysis ; Neoplasm Metastasis ; Neoplasm Recurrence, Local ; Phyllodes Tumor ; Prognosis ; Retrospective Studies ; Risk Factors

7

Cite

Cite

Copy

Share

Share

Copy

A modified method for locating parapharyngeal space neoplasms on magnetic resonance images: implications for differential diagnosis.

Xue-Wen LIU ; ; Ling WANG ; Hui LI ; Rong ZHANG ; Zhi-Jun GENG ; De-Ling WANG ; Chuan-Miao XIE

Chinese Journal of Cancer.2014;33(10):511-520. doi:10.5732/cjc.014.10017

The parapharyngeal space (PPS) is an inverted pyramid-shaped deep space in the head and neck region, and a variety of tumors, such as salivary gland tumors, neurogenic tumors, nasopharyngeal carcinomas with parapharyngeal invasion, and lymphomas, can be found in this space. The differential diagnosis of PPS tumors remains challenging for radiologists. This study aimed to develop and test a modified method for locating PPS tumors on magnetic resonance (MR) images to improve preoperative differential diagnosis. The new protocol divided the PPS into three compartments: a prestyloid compartment, the carotid sheath, and the areas outside the carotid sheath. PPS tumors were located in these compartments according to the displacements of the tensor veli palatini muscle and the styloid process, with or without blood vessel separations and medial pterygoid invasion. This protocol, as well as a more conventional protocol that is based on displacements of the internal carotid artery (ICA), was used to assess MR images captured from a series of 58 PPS tumors. The consequent distributions of PPS tumor locations determined by both methods were compared. Of all 58 tumors, our new method determined that 57 could be assigned to precise PPS compartments. Nearly all (13/14; 93%) tumors that were located in the pre-styloid compartment were salivary gland tumors. All 15 tumors within the carotid sheath were neurogenic tumors. The vast majority (18/20; 90%) of trans-spatial lesions were malignancies. However, according to the ICA-based method, 28 tumors were located in the pre-styloid compartment, and 24 were located in the post-styloid compartment, leaving 6 tumors that were difficult to locate. Lesions located in both the pre-styloid and the post-styloid compartments comprised various types of tumors. Compared with the conventional ICA-based method, our new method can help radiologists to narrow the differential diagnosis of PPS tumors to specific compartments.
Carcinoma ; Diagnosis, Differential ; Humans ; Lymphoma ; diagnosis ; diagnostic imaging ; Magnetic Resonance Spectroscopy ; Nasopharyngeal Neoplasms ; diagnosis ; diagnostic imaging ; Neck ; diagnostic imaging ; Nervous System Neoplasms ; diagnosis ; diagnostic imaging ; Pharynx ; diagnostic imaging ; Radiography ; Salivary Gland Neoplasms ; diagnosis ; diagnostic imaging

Carcinoma ; Diagnosis, Differential ; Humans ; Lymphoma ; diagnosis ; diagnostic imaging ; Magnetic Resonance Spectroscopy ; Nasopharyngeal Neoplasms ; diagnosis ; diagnostic imaging ; Neck ; diagnostic imaging ; Nervous System Neoplasms ; diagnosis ; diagnostic imaging ; Pharynx ; diagnostic imaging ; Radiography ; Salivary Gland Neoplasms ; diagnosis ; diagnostic imaging

8

Cite

Cite

Copy

Share

Share

Copy

Incidence and mortality of liver cancer in China, 2010.

Kuang-Rong WEI ; Xia YU ; Rong-Shou ZHENG ; Xia-Biao PENG ; Si-Wei ZHANG ; Ming-Fang JI ; Zhi-Heng LIANG ; Zhi-Xiong OU ; Wan-Qing CHEN

Chinese Journal of Cancer.2014;33(8):388-394. doi:10.5732/cjc.014.10088

Liver cancer is a common malignant tumor in China and a major health concern. We aimed to estimate the liver cancer incidence and mortality in China in 2010 using liver cancer data from some Chinese cancer registries and provide reference for liver cancer prevention and treatment. We collected and evaluated the incidence and mortality data of liver cancer in 2010 from 145 cancer registries, which were included in the 2013 Chinese Cancer Registry Annual Report, calculated crude, standardized, and truncated incidences and mortalities, and estimated new liver cancer cases and deaths from liver cancer throughout China and in different regions in 2010 from Chinese practical population. The estimates of new liver cancer cases and deaths were 358,840 and 312,432, respectively, in China in 2010. The crude incidence, age-standardized rate by Chinese standard population (ASR China), and age-standardized rate by world standard population (ASR world) were 27.29/100,000, 21.35/100,000, and 20.87/100,000, respectively; the crude, ASR China, and ASR world mortalities were 23.76/100,000, 18.43/100,000, and 18.04/100,000, respectively. The incidence and mortality were the highest in western regions, higher in rural areas than in urban areas, and higher in males than in females. The age-specific incidence and mortality of liver cancer showed a rapid increase from age 30 and peaked at age 80-84 or 85+. Our results indicated that the 2010 incidence and mortality of liver cancer in China, especially in undeveloped rural areas and western regions, were among high levels worldwide. The strategy for liver cancer prevention and treatment should be strengthened.
China ; epidemiology ; Female ; Humans ; Incidence ; Liver Neoplasms ; epidemiology ; mortality ; Male ; Registries ; Rural Population ; Sex Distribution ; Urban Population

China ; epidemiology ; Female ; Humans ; Incidence ; Liver Neoplasms ; epidemiology ; mortality ; Male ; Registries ; Rural Population ; Sex Distribution ; Urban Population

9

Cite

Cite

Copy

Share

Share

Copy

Nasopharyngeal carcinoma incidence and mortality in China in 2010.

Kuang-Rong WEI ; Rong-Shou ZHENG ; Si-Wei ZHANG ; Zhi-Heng LIANG ; Zhi-Xiong OU ; Wan-Qing CHEN

Chinese Journal of Cancer.2014;33(8):381-387. doi:10.5732/cjc.014.10086

Nasopharyngeal carcinoma (NPC) is common in South China. Although regional epidemiological data on NPC in China is available, national epidemiological data have been unavailable up to now. The goal of this study was to analyze the NPC incidence and mortality data in some domestic cancer registries, estimate these rates in China in 2010, and provide scientific information that can be harnessed for NPC control and prevention. To accomplish this goal, NPC incidence and mortality data for 2010 were collected from 145 Chinese cancer registries from which data were included in the 2013 National Cancer Registry Annual Report. Such indices as its incident and death numbers, crude rates, age-standardized rates and truncated rates were calculated and analyzed. The incidence and mortality in China and constituent areas were estimated according to the national population in 2010. An estimated 41,503 new cases and 20,058 deaths were attributed to NPC in China in 2010, accounting for 1.34% of all new cancer cases and 1.03% of all cancer-related deaths that year in China. Crude incidence and mortality were 3.16/100,000 and 1.53/100,000, respectively. World age-standardized incidence and mortality were 2.44/100,000 and 1.18/100,000, respectively. Incidence and mortality were higher among males than among females and slightly higher in urban areas than in rural areas. Among seven Chinese administrative regions, NPC incidence and mortality were obviously higher in South China than in other regions and lowest in North China. The male and female age-specific incidence and mortality both rose quickly from age 25-29 years, but peaked at different ages and varied by location. These results demonstrated that NPC incidence and mortality in China especially in South China were at high levels in the world, and suggested that control and prevention efforts should be enhanced.
Carcinoma ; China ; epidemiology ; Female ; Humans ; Incidence ; Male ; Nasopharyngeal Neoplasms ; epidemiology ; mortality ; Registries ; Rural Population ; Urban Population

Carcinoma ; China ; epidemiology ; Female ; Humans ; Incidence ; Male ; Nasopharyngeal Neoplasms ; epidemiology ; mortality ; Registries ; Rural Population ; Urban Population

10

Cite

Cite

Copy

Share

Share

Copy

Genomics in personalized cancer medicine and its impact on early drug development in China: report from the 6th Annual Meeting of the US Chinese Anti-Cancer Association (USCACA) at the 50th ASCO Annual Meeting.

Wei ZHANG ; Shi-Yuan CHENG ; Li-Fang HOU ; Li YAN ; Yun-Guang TONG

Chinese Journal of Cancer.2014;33(8):371-375. doi:10.5732/cjc.014.10110

The 6th Annual Meeting of the United States Chinese Anti-Cancer Association (USCACA) was held in conjunction with the 50th Annual Meeting of American Society of Clinical Oncology (ASCO) on May 30, 2014 in Chicago, Illinois, the United States of America. With a focus on personalized medicine, the conference featured novel approaches to investigate genomic aberrations in cancer cells and innovative clinical trial designs to expedite cancer drug development in biomarker-defined patient populations. A panel discussion further provided in-depth advice on advancing development of personalized cancer medicines in China. The conference also summarized USCACA key initiatives and accomplishments, including two awards designated to recognize young investigators from China for their achievements and to support their training in the United States. As an effort to promote international collaboration, USCACA will team up with Chinese Society of Clinical Oncology (CSCO) to host a joint session on "Breakthrough Cancer Medicines" at the upcoming CSCO Annual Meeting on September 20th, 2014 in Xiamen, China.
Antineoplastic Agents ; Awards and Prizes ; Chicago ; China ; Drug Discovery ; Genomics ; Humans ; Medical Oncology ; Neoplasms ; Precision Medicine ; Societies, Medical ; United States

Antineoplastic Agents ; Awards and Prizes ; Chicago ; China ; Drug Discovery ; Genomics ; Humans ; Medical Oncology ; Neoplasms ; Precision Medicine ; Societies, Medical ; United States

Country

China

Publisher

中山医科大学肿瘤防治中心

ElectronicLinks

http://AIZH.chinajournal.net.cn

Editor-in-chief

E-mail

cjc@cjcsysu.cn

Abbreviation

Chinese Journal of Cancer

Vernacular Journal Title

癌症

ISSN

1000-467X

EISSN

Year Approved

2009

Current Indexing Status

Currently Indexed

Start Year

1982

Description

历史沿革【现用刊名:癌症;创刊时间:1982】,该刊被以下数据库收录【CA 化学文摘(美)(2009);CBST 科学技术文献速报(日)(2009);中国科学引文数据库(CSCD—2008)】,核心期刊【中文核心期刊(2008);中文核心期刊(2004);中文核心期刊(2000);中文核心期刊(1996);中文核心期刊(1992)】,期刊荣誉【Caj-cd规范获奖期刊】。

Related Sites

WHO WPRO GIM

Help Accessibility
DCMS Web Policy
CJSS Privacy Policy

Powered by IMICAMS( 备案号: 11010502037788, 京ICP备10218182号-8)

Successfully copied to clipboard.